Harminder Singh
Public Health Agency of Canada
7 Papers
Harminder Singh is an academic researcher from Public Health Agency of Canada. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 6, co-authored 7 publications. Previous affiliations of Harminder Singh include University of Calgary & McGill University.
Chat about Author
Papers
Recommendations on screening for prostate cancer with the prostate-specific antigen test
Neil Bell,Sarah Connor Gorber,Amanda Shane,Michel Joffres,Harminder Singh,James A. Dickinson,Elizabeth Shaw,Lesley Dunfield,Marcello Tonelli +8 more
TL;DR: See related commentary on page [1201] and at [www.cmaj.ca/lookup/doi/10.1503/cmaja.141252].
Recommendations on screening for cervical cancer.
James A. Dickinson,Tsakonas E,Conner Gorber S,Gabriela Lewin,Elizabeth Shaw,Harminder Singh,Michel Joffres,Richard Birtwhistle,Marcello Tonelli,Mai,McLachlin M +10 more
TL;DR: This guideline provides updated recommendations for screening for cervical cancer in Canada based on new information about the epidemiology and diagnosis of cervical cancer and a new systematic search of the literature.
233
Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer
Scott Klarenbach,Nicki Sims-Jones,Gabriela Lewin,Harminder Singh,Guylène Thériault,Marcello Tonelli,Marion Doull,Susan Courage,Alejandra Jaramillo Garcia,Brett D. Thombs +9 more
TL;DR: Breast cancer mortality rates among Canadian women have declined from 41.7 per 100 000 in 1988 to an estimated 23.2 per 100000 in 2017, while age-standardized incidence has remained relatively stable, at around.
Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening
James A. Dickinson,Amanda Shane,Marcello Tonelli,Sarah Connor Gorber,Michel Joffres,Harminder Singh,Neil Bell +6 more
- 02 Mar 2016
TL;DR: It is suggested that screening caused artifactual increase in incidence, but no more than a part of reductions in prostate cancer mortality, which may be due to changing treatment or certification of death.